Association of British Clinical Diabetologists (ABCD) and Renal Association clinical guidelines: Hypertension management and renin-angiotensin-aldosterone system blockade in patients with diabetes, nephropathy and/or chronic kidney disease


  • Indranil Dasgupta Heartlands Hospital, Birmingham
  • Debasish Banerjee St George’s Hospital, London
  • Tahseen A Chowdhury Royal London Hospital, London
  • Parijat De City Hospital, Birmingham
  • Mona Wahba St Helier Hospital, Carshalton
  • Stephen Bain Swansea University, Swansea
  • Andrew Frankel Imperial College Healthcare NHS Trust, London
  • Damian Fogarty Belfast Health and Social Care Trust, Belfast
  • Ana Pokrajac West Hertfordshire Hospitals
  • Peter H Winocour ENHIDE, QE2 Hospital, Welwyn Garden City



diabetes, blood pressure, albuminuria, chronic, kidney disease, dialysis


Diabetes is the commonest cause of end-stage renal disease; over a quarter of patients who are on dialysis in the UK have diabetes. Diabetic kidney disease is associated with high cardiovascular morbidity and mortality. Hypertension is a modifiable risk factor for cardiovascular complications and progression of diabetic kidney disease.

The Association of British Clinical Diabetologists and the Renal Association have jointly developed guidelines for management of hypertension through different stages of diabetic kidney disease. Here we present a summary of clinical practice recommendations, audit standards, and areas that require further research.

Author Biography

Peter H Winocour, ENHIDE, QE2 Hospital, Welwyn Garden City

Clinical director and consultant



Ritz E, Orth SR. Nephropathy in patients with type 2 diabetes mellitus. N Engl J Med 1999;341:1127–33.

Gilg J, Caskey F, Fogarty D. UK Renal Registry 18th Annual Report: Chapter 1 UK Renal Replacement Therapy Incidence in 2014: National and Centre-specific Analyses. Nephron 2016;132(Suppl 1):9–40.

Stamler J, Vaccaro O, Neaton JD, Wentworth D. Diabetes, other risk factors, and 12-yr cardiovascular mortality for men screened in the Multiple Risk Factor Intervention Trial. Diabetes Care 1993;16:434–44.







Most read articles by the same author(s)

1 2 > >>